Now Playing
Opinion|Videos|December 24, 2024
Diagnosis and Risk Stratification for Early-Stage HR+/HER2- Breast Cancer
Panelists discuss how the NCCN guidelines for risk stratification in HR+/HER2- early-stage breast cancer inform clinical decision-making, with an emphasis on biomarker testing, the use of tools like RSClin N+, and the evolving role of CDK4/6 inhibitors and adjuvant therapies. They also address challenges in risk assessment and the integration of newer treatment strategies, such as CDK4/6 inhibitors and PARP inhibitors in the early-stage setting.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the key NCCN guidelines for risk-stratifying patients with HR+, HER2- early-stage breast cancer (eBC)?
- How closely does overall real-world practice follow these guidelines?
- Can you please describe your approach to diagnosing and stratifying HR+, HER2- breast cancer at an early stage?
- What clinical scenarios make risk stratification complex?
- How do you define “high risk” in this setting?
- What are your thoughts on the RSClin N+ tool (ASCO 2024)
- What biomarkers do you typically test for in HR+/HER2- eBC? (hormone receptor, progesterone receptor, HER2, others?)
- What testing methodologies are most used (next-generation sequencing, fluorescence in situ hybridization, immunohistochemistry, panels, etc)?
- How do they differ, and what can you learn from each?
- Do you ever check circulating tumor DNA?
- How do various testing results guide your treatment approach?
- Please briefly describe the predominant role of CDK4/6i in HR+/HER2- eBC.
- Given your experience and the positive trials in the metastatic setting, how comfortable are you with using CDK4/6i in eBC?
- Could you provide an overview of current treatment options for eBC?
- What are the limitations of current treatments?
- How are newer strategies like adjuvant CDK4/6 and PARP inhibitors changing the paradigm?
- What is the rationale for combining CDK4/6 inhibitors with endocrine therapy in eBC?
Advertisement
Related to this article
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Drs Nunnery and Iyengar discuss FAQs about the metabolic effects of breast cancer therapy and the expanding role of GLP-1 receptor agonists in oncology.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.
The CHMP has recommended datopotamab deruxtecan for patients with first-line metastatic TNBC who are not candidates for immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
Five Under 5: Top Oncology Videos for the Week of 6/28
3
The OncFive: Top Oncology Articles for the Week of 6/28
4
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
5